ArticleWiener klinische Wochenschrift2026
Outcomes of living related kidney donors of recipients with familial mediterranean fever-associated Amyloid A Amyloidosis.
Article in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiving kidney donation among carefully selected individuals is generally considered safe but post-donation health risks vary by factors including family history. Data on long-term outcomes of related living kidney donors of recipients with familial Mediterranean fever (FMFLRD) are limited.
methodsThis retrospective multicenter study reviewed the medical records of living donors who donated between 2010 and 2021 across six transplantation centers. Cardiovascular and kidney outcomes were compared between 37 FMFLRD and a propensity-matched control group of 74 donors to recipients without FMF (non-FMFLRD). Propensity score matching was based on donor age, sex, and follow-up time. Outcome measures included major cardiac events (MACE), new-onset hypertension, new-onset diabetes mellitus, proteinuria and estimated glomerular filtration rate (eGFR).
resultsThe median follow-up duration of all donors was 4.0 years (interquartile range, IQR 2.0-11.0 years). The mean age of the FMFLRD group was 48.9 ± 9.3 years, The FMFLRD group showed a significantly lower proportion of MACE (2.7% vs. 17.6%, p = 0.026) and new-onset hypertension (13.5% vs. 39.2%, p = 0.004) and a trend towards a lower proportion of new-onset diabetes mellitus (2.7% vs. 14.9%, p = 0.052) compared to the non-FMFLRD group. There were no significant differences in long-term kidney function, as evidenced by similar eGFR and proteinuria levels between the groups.
conclusionThe FMFLRD group showed similar kidney outcomes and lower rates of cardiovascular and metabolic complications during follow-up compared with matched non-FMFLRD; however, given the retrospective design and relatively short follow-up duration, long-term donor safety remains uncertain and the results should be interpreted cautiously.
Indexed as
Identifiers
42565838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.